HROW on Nasdaq

Harrow Health

American pharmaceutical company

Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee. Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 18, 2026.

Overview

Jan 1, 1998Founded1

Compare with Vireo Growth Inc., LIGAND PHARMACEUTICALS INC or Arvinas (United States), or pick any stock.

  • TickerHROW on Nasdaq1
  • Industrypharmaceutical industry1
  • HeadquartersNashville1
  • Websitewww.harrow.com
  • Incorporated inDE4
  • Business address1A Burton Hills Blvd, Suite 200, Nashville, Tn4
  • Filer categoryLarge accelerated filer4

See how the biggest companies compare on our leaderboards

Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

75.1%Gross margin6
11.2%Operating margin6
-1.9%Net margin6
36.4%Revenue growth, 20256
-9.8%Return on equity6
4.77×Debt to equity6
$43.0MFree cash flow6

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Product Sales Net brought in 58% of the revenue Harrow Health broke down this way in fiscal 2025.

  1. Product Sales Net$271.9M658%up 37% from 2024
  2. Vevye$88.7M619%up 216% from 2024
  3. Iheezo$81.3M617%up 65% from 2024
  4. Other Products$25.3M65%down 33% from 2024
  5. Other Revenue$394.0K60%down 57% from 2024
  6. Other Revenues$394.0K60%down 60% from 2024
Products and services by year
Products and services202320242025
Product Sales Net$117.4M$198.6M$271.9M
Vevye$1.8M$28.1M$88.7M
Iheezo$20.6M$49.3M$81.3M
Other Products$15.1M$37.8M$25.3M
Other Revenue$12.7M$915.0K$394.0K
Other Revenues$12.7M$995.0K$394.0K

Business segments

Branded brought in 72% of the revenue Harrow Health broke down this way in fiscal 2025.

  1. Branded$195.8M672%up 69% from 2024
  2. Imprimis Rx$76.5M628%down 8% from 2024
Business segments by year
Business segments202320242025
Branded$50.3M$116.1M$195.8M
Imprimis Rx$79.9M$83.5M$76.5M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue25¢$67.9M
  • Research and development8¢$20.9M
  • Selling, general and admin56¢$152.9M
  • Other costs10¢$26.7M
  • Income tax1¢$3.8M

Out of $272.3M in revenue.6 The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

  • Capital spending2¢$887.0K
  • Kept or used elsewhere98¢$43.0M

Out of $43.9M of cash from operations.6

Financial statements

Revenue789106$272.3M in 2025+432% since 2019
0$100.0M$200.0M$300.0M2019: $51.2M$51.2M20192020: $48.9M$48.9M2020−4%2021: $72.5M$72.5M2021+48%2022: $88.6M$88.6M2022+22%2023: $130.2M$130.2M2023+47%2024: $199.6M$199.6M2024+53%2025: $272.3M$272.3M2025+36%
Gross profit789106$204.4M in 2025+494% since 2019
0$100.0M$200.0M$300.0M2019: $34.4M$34.4M20192020: $34.4M$34.4M2020−0%2021: $54.3M$54.3M2021+58%2022: $63.2M$63.2M2022+16%2023: $90.6M$90.6M2023+43%2024: $150.4M$150.4M2024+66%2025: $204.4M$204.4M2025+36%
Operating income789106$30.5M in 2025
-$10.0M0$10.0M$20.0M$30.0M$40.0M2019: -$4.8M-$4.8M20192020: $385.0K$385.0K20202021: $1.6M$1.6M2021+319%2022: $1.9M$1.9M2022+19%2023: $431.0K$431.0K2023−78%2024: $8.8M$8.8M2024+1947%2025: $30.5M$30.5M2025+246%
Net income789106-$5.1M in 2025
-$30.0M-$20.0M-$10.0M0$10.0M2019: $168.0K$168.0K20192020: -$3.4M-$3.4M20202021: -$18.0M-$18.0M2021+436%2022: -$14.1M-$14.1M2022−22%2023: -$24.4M-$24.4M2023+73%2024: -$17.5M-$17.5M2024−28%2025: -$5.1M-$5.1M2025−71%

Every line of the income statement as filed: the last 3 fiscal years, latest first.6

Period ending2025-12-312024-12-312023-12-31
Total revenues$272.3M$199.6M$130.2M
Cost of sales-$67.9M-$49.2M-$39.6M
Gross profit$204.4M$150.4M$90.6M
Selling, general and administrative$152.9M$129.1M$83.1M
Research and development$20.9M$12.2M$6.7M
Impairment of long-lived assets$253.0K$380.0K
Total operating expenses$173.9M$141.5M$90.1M
Income from operations$30.5M$8.8M$431.0K
Interest expense, net-$24.2M-$22.8M-$21.3M
Investment (loss) gain from Eton Pharmaceuticals-$3.2M$3.1M
Loss on extinguishment of debt-$7.8M-$5.5M
Other income (expense), net$47.0K-$185.0K-$444.0K
Total other expense, net-$31.9M-$26.1M-$24.1M
Loss before income taxes-$1.4M-$17.3M-$23.7M
Income tax expense-$3.8M-$161.0K-$701.0K
Net loss-$5.1M-$17.5M-$24.4M
Basic net loss per share of common stock-$0.14-$0.49-$0.75
Diluted net loss per share of common stock-$0.14-$0.49-$0.75
Weighted average number of shares of common stock outstanding, basic36.8M shares35.7M shares32.6M shares
Weighted average number of shares of common stock outstanding, diluted36.8M shares35.7M shares32.6M shares

Compare Harrow Health with another company

Leadership

Who has led Harrow Health, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Juliet Singh2007–2009
  2. John N. Bonfiglio2010
  3. Mark L. Baum2012–2013
  4. Robert J. Kammer2013
  5. John P. Saharek2024–2025
  6. Francis William Mullery Jr.2025–now

Chair

  1. Robert J. Kammer2012

President

  1. Juliet Singh2007–2009
  2. John N. Bonfiglio2010
  3. John P. Saharek2021–2025
  4. Andrew Boll2025–now

Chief financial officer

  1. John T. Lomoro2007–2009
  2. Andrew Boll2015–now

Chief operating officer

  1. Clayton D. Edwards2017
200020052010201520202025
Board members and other officers (26)

Products and brands

Through its compounding subsidiary ImprimisRx, the company was the first pharmaceutical compounding company to make cGMP ophthalmic eye drops and other sterile compounded products available at a national scale through its FDA-registered outsourcing facility.

ImprimisRx's primary business is that of compounding drugs; that is, combining or altering the formulation of existing drugs to market them to specific populations. As of 2015, the company's business model was driven by development and sale of inexpensive alternatives to off-patent medicines where there was previously only a single manufacturer who could therefore charge outsize prices.

In August 2020, ImprimisRx announced that it was expanding its business beyond compounded drugs and that through a partnership with EyePoint Pharmaceuticals, it would begin to sell Dexycu, an FDA-approved steroid product.

As of 2020, Imprimis operated two pharmaceutical production and distribution facilities, both of which are located in Ledgewood, New Jersey. The company has licenses to operate federally, through the US DEA, and through state pharmacy boards in all 50 of the United States.

From Wikipedia’s article on Harrow, Inc., shared under CC BY-SA 4.0.5

Former names

  • HARROW HEALTH, INC.Dec 31, 2018 to Sep 20, 20234
  • Imprimis Pharmaceuticals, Inc.Mar 27, 2012 to Dec 17, 20184
  • TRANSDEL PHARMACEUTICALS INCSep 13, 2007 to Feb 27, 20124
  • Bywater Resources, IncJul 21, 2006 to Sep 12, 20074

Timeline

  1. Oct 10, 2025New chief executive Francis William Mullery Jr. becomes CEO14
  2. Feb 21, 2024New chief executive John P. Saharek becomes CEO15
  3. Mar 15, 2013New chief executive Robert J. Kammer becomes CEO16
  4. Apr 27, 2012New chief executive Mark L. Baum becomes CEO17
  5. Oct 22, 2010New chief executive John N. Bonfiglio becomes CEO18
  6. Dec 27, 2007New chief executive Juliet Singh becomes CEO19
  7. Jan 1, 1998Founded Founded1

Filings

242 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 77 major events, 97 insider forms, 20 large holders, 28 other. The latest 20:

  1. Oct 5, 20268-K EDGAR
  2. Sep 4, 20268-K EDGAR
  3. Aug 21, 2026144 EDGAR
  4. Aug 17, 20264 EDGAR
  5. Aug 10, 202610-Q EDGAR
  6. Aug 10, 20268-K EDGAR
  7. Aug 6, 20268-K EDGAR
  8. Jul 31, 2026SCHEDULE 13G/A EDGAR
  9. Jun 22, 20264 EDGAR
  10. Jun 22, 20264 EDGAR
  11. Jun 22, 20264 EDGAR
  12. Jun 22, 20268-K EDGAR
  13. Jun 3, 20268-K EDGAR
  14. May 19, 20264 EDGAR
  15. May 19, 20264 EDGAR
  16. May 18, 20264 EDGAR
  17. May 15, 20264 EDGAR
  18. May 15, 20264 EDGAR
  19. May 11, 202610-Q EDGAR
  20. May 11, 2026SCHEDULE 13G/A EDGAR

The 242 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 20 such filings since October 2021, the latest 10:

  1. Jul 31, 2026SCHEDULE 13G/A
  2. May 11, 2026SCHEDULE 13G/A
  3. Mar 27, 2026SCHEDULE 13G/A
  4. Mar 11, 2026SCHEDULE 13G
  5. Apr 7, 2025SCHEDULE 13D/A
  6. Dec 5, 2024SC 13G/A
  7. Oct 8, 2024SC 13G/A
  8. Apr 30, 2024SC 13D/A
  9. Feb 13, 2024SC 13G
  10. Feb 13, 2024SC 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.2,740,117$116.4M0.0%+187,358
Opaleye Management Inc.2,400,000$101.9M9.2%−432,230
Private Capital Management, LLC1,598,770$67.9M6.2%+36,770
Vanguard Capital Management LLC1,417,212$60.2M0.0%+14,156
Deep Track Capital, LP969,000$41.2M0.6%New
State Street Corp939,888$39.9M0.0%+84,841
Geode Capital Management, LLC905,560$38.5M0.0%+53,526
Bamco Inc /ny/809,350$34.4M0.1%New
Dimensional Fund Advisors LP667,036$28.3M0.0%+87,516
Jupiter Topco LLC579,127$24.6M0.0%New
Divisadero Street Capital Management, LP439,155$18.7M0.4%New
Rice Hall James & Associates, LLC387,545$16.5M0.8%+19,368
Marshall Wace, Llp369,435$15.7M0.0%−275,483
Citadel Advisors LLC359,874$15.3M0.0%+138,616
Northern Trust Corp323,206$13.7M0.0%+26,341
Schonfeld Strategic Advisors LLC319,625$13.6M0.1%New
Vanguard Portfolio Management LLC318,610$13.5M0.0%+29,735
Charles Schwab Investment Management Inc273,696$11.6M0.0%+3,160
Vanguard Fiduciary Trust Co235,418$10.0M0.0%+7,797
Westside Investment Management, Inc.224,051$9.5M1.2%+38,125
FirstWave Capital Management LLC211,981$9.0M4.0%+68,058
Blackhawk Capital Partners, LLC203,241$8.6M2.8%+30,909
Susquehanna International Group, Llp190,116$8.1M0.0%−267,666
Stifel Financial Corp180,893$7.7M0.0%−53,767
Goldman Sachs Group Inc154,777$6.6M0.0%−186,930

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47